Janssen submits supplemental New Drug Application to FDA seeking new indications for Xarelto (rivaroxaban) for patients with chronic coronary and/or peripheral artery disease (CAD/PAD). Janssen Research & Development, LLC today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for two new Xarelto (rivaroxaban) vascular indications: Reducing the…
